Recent Developments in the Classification, Evaluation, Pathophysiology, and Management of Scleroderma Renal Crisis

Current Rheumatology Reports

Volumn 18, Issue 1, 2016, Pages 1-6

  Ghossein, Cybele ^a   Varga, John ^a   Fenves, Andrew Z ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Angiotensin converting enzyme inhibitor (ACEI); Diffuse cutaneous disease (dcSSc); Immune dysregulation; Malignant hypertension; Renal biopsy; Scleroderma renal crisis (SRC); Systemic sclerosis; Thrombotic microangiopathy

Indexed keywords

ALISKIREN; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; AUTOANTIBODY; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA DIRECTED RNA POLYMERASE III; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 3; VASODILATOR AGENT;

ANTIBODY SCREENING; BLOOD PRESSURE REGULATION; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE CONTROL; GENETIC ASSOCIATION; GENETIC SCREENING; HUMAN; HYPERTENSION; IMMUNE RESPONSE; IMMUNOREGULATION; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; NONHUMAN; PATHOGENESIS; PROGNOSIS; REVIEW; RISK ASSESSMENT; SCLERODERMA RENAL CRISIS; SYSTEMIC SCLEROSIS; TREATMENT INDICATION; ACUTE KIDNEY INJURY; COMPLICATION; PATHOLOGY; PATHOPHYSIOLOGY; RISK FACTOR; SCLERODERMA, SYSTEMIC;

ACUTE KIDNEY INJURY; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HUMANS; KIDNEY TRANSPLANTATION; PROGNOSIS; RISK FACTORS; SCLERODERMA, SYSTEMIC;

EID: 84952013335     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-015-0551-y     Document Type: Review

References (37)

1. Steen V, Costantino J, Shapiro A, Medsger T. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme inhibitors. Ann Intern Med. 1990;113:352–7.
2. Cozzi F, Marson P, Cardarelli S, Favaro M, Tison T, Tonello M, et al. Prognosis of scleroderma renal crisis: a long term observational study. Nephrol Dial Transplant. 2012;27:4398–403.
3. Guillevin L, Berezne A, Seror R, Teixeira L, Pourrat J, Mahr A, et al. Scleroderma renal crisis: a retrospective multicenter study on 91 patients and 427 controls. Rheumatology. 2012;51:460–7. This is a retrospective evaluation of 91 SRC patients compared to non-SRC SSc control patients. It describes characteristics, prognosis, and outcome of SRC patients.
4. Penn H, Howie A, Kingdon EJ, Bunn C, Stratton R, Black C, et al. Scleroderma renal crisis: patient characteristics and long term outcomes. Q J Med. 2007;100:485–94.
5. Texeira L, Mouhon L, Mahr A, Berezne A, Agard C, Mehrenberger M, et al. Mortality and risk factors of scleroderma renal crisis a French retrospective study of 50 patients. Ann Rheum Dis. 2008;67:110–6.
6. Logee KM, Laksminarayanan S. Scleroderma renal crisis as an initial presentation of systemic sclerosis: a case report and review of the literature. Clin Exp Rheumatol. 2015.
7. Steen VD, Mayes MD, Merkel PA. Assessment of kidney involvement. Clin Exp Rheumatol. 2003;21 suppl 29:S29–31.
8. Hudson M, Baron M, Tatibouet S, Furst D, Khanna D. Exposure to ACE inhibitors prior to onset of scleroderma renal crisis—results from the International Scleroderma Renal Crisis Survey. Semin Arthritis Rheum. 2014;43:666–72. This is a prospective cohort study showing that prior exposure to ACE inhibitors was associated with an increased risk of death after onset of scleroderma renal crisis.
9. KDIGO Clinical Practice Guideline for acute kidney injury. Kidney International 2012: 2 supplement
10. Marighela TF, Genaro PS, Pinheiro MM, Szejnfeld VL, Kayser C. Risk factors for body composition abnormalities in systemic sclerosis. Clin Rheumatol. 2013;32:1037–44.
11. Amin A, El-Sayed S, Taher N, Sedki M, Nasr H. Tc-99m diethylenetriamine pentaacetic acid (DTPA) renal function reserve estimation: is it a reliable predictive tool for assessment of preclinical renal involvement in scleroderma patients? Clin Rheumatol. 2012;31:961–6.
12. Guerra S et al. Defining genetic risk for scleroderma renal crisis. Rheumatology. 2014;54:654–66.
13. Fonseca C, Renzoni E, et al. Endothelin axis polymorphisms in patients with scleroderma. Arthritis Rheum. 2006;54:3034–42.
14. Mouthon L et al. Endothelin-1 expression in scleroderma renal crisis. Hum Pathol. 2011;42:95–102.
15. Kobayashi H, Nishimaki T, Kaise S, Suzuki T, et al. Immunohistological study of endothelin-1 and endothelin-A and B receptors in two patients with scleroderma renal crisis. Clin Rheumatol. 1999;18:425–7.
16. Becker MO, Kill A, et al. Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Am J Resp Crit Care Med. 2014;190:808–17.
17. Guillevin L, Mouthon L. Scleroderma renal crisis. Rheum Dis Clin N Am. 2015. 475–488.
18. Batal I, Domsic R, Shafer A, Medsger T, Kiss L, Randhawa P, et al. Renal biopsy findings prediction outcome in scleroderma renal crisis. Hum Pathol. 2009;40:332–40.
19. Yamada Y, Suzuki K, Nobata H, Kawai H, Wakamatsu R, Miura N, et al. Gemcitabine-induced hemolytic uremic syndrome mimicking scleroderma renal crisis presenting with Raynaud’s phenomenon, positive antinuclear antibodies and hypertensive emergency. Intern Med. 2014;53(5):445–8.
20. Abudiab M, Krause ML, Fidler ME, Nath KA, Norby SM. Differentiating scleroderma renal crisis from other causes of thrombotic microangiopathy in a postpartum patient. Clin Nephrol. 2013;80(4):293–7.
21. Keeler E, Fioravanti G, Samuel B, Longo S. Scleroderma renal crisis or thrombotic thrombocytopenic purpura: seeing through the masquerade. Lab Med. 2015;46(2):e39–44.
22. Bhasavar S, Carmona R. Anti-RNA polymerase III antibodies in the diagnosis of scleroderma renal crisis in the absence of skin disease. JCR: J Clin Rheumatol. 2014;20:379–82.
23. Fred H, Rambo O. Acute renal failure due to scleroderma kidney disease; a report of one case with autopsy findings. AMA Arch Intern Med. 1957;100(5):813–8.
24. Batal I, Domsic R, Medsger T Bastacky S. Scleroderma renal crisis: a pathology perspective. Int J Rheumatol. 2010. 1–5
25. Steen V, Medsger T. Changes in causes of death in systemic sclerosis 1972–2002. Ann Rheum Dis. 2007;66:940–4.
26. Wasner C, Cooke CR, Fries JF. Successful medical treatment of scleroderma renal crisis. N Engl J Med. 1978;299(16):873–5. This report describes the treatment of SRC with oral anti hypertensive medications other than Ace inhibitors.
27. Lopez-Ovejero J, Saal SD, D’Angelo WA, Cheigh JS, et al. Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade. N Engl J Med. 1979;300:1417–9. This report describes the first successful treatment of SRC with ACE inhibitors.
28. Caskey FJ, Thacker EJ, Johnston PA, Barnes JN. Failure of losartan to control blood pressure in scleroderma renal crisis. Lancet. 1997;349(9052):620.
29. Cheung WY, Gibson IW, Rush D, Jeffery J, Karpinski M. Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade. Am J Kidney Dis. 2005;45:930–4.
30. Dhaun N, MacIntyre IM, Bellamy CO, Kluth DC. Endothelin receptor antagonism and renin inhibition as treatment options for scleroderma kidney. Am J Kidney Dis. 2009;54(4):726–31.
31. Penn H, Quillian N, et al. Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility. Quart L Med. 2013;106(9):839–48. This study is a pilot open-label study looking at ET1 expression in patients with SRC and determined the safety and possible benefit of the use of ET1 antagonist in this disease.
32. Bose N, Chiesa-Vottero A, Chatterjee S. Scleroderma renal crisis. Semin Arthritis Rheum. 2015;44:687–94.
33. Steen VD, Medsger Jr TA. Long-term outcomes of scleroderma renal crisis. Ann Intern Med. 2000;133(8):600–3.
34. Denton C, Black C. Scleroderma—clinical and pathological advances. Best Pract Res Clin Rheumatol. 2004;18:271–90.
35. Penn H, Denton CP. Diagnosis, management and prevention of scleroderma renal disease. Curr Opin Rheumatol. 2008;20(6):692–6.
36. Fenves AZ, Murphy JS, Emmett M. Scleroderma renal crisis and recovery from end-stage renal disease. Semin Dial. 1998;11(3):189–91.
37. Pham PT, Pham PC, Danovitch GM, Gritsch A, et al. Predictors and risk factors for recurrent scleroderma renal crisis in the kidney allograft: case report and review of the literature. Am J Transplant. 2005;5(10):2565–9.